CACNA1A

protein-coding

calcium voltage-gated channel subunit alpha1 A, the group of Calcium voltage-gated channel alpha1 subunits

Gene summary

Voltage-dependent calcium channels mediate the entry of calcium ions into excitable cells, and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, and gene expression. Calcium channels are multisubunit complexes composed of alpha-1, beta, alpha-2/delta, and gamma subunits. The channel activity is directed by the pore-forming alpha-1 subunit, whereas, the others act as auxiliary subunits regulating this activity. The distinctive properties of the calcium channel types are related primarily to the expression of a variety of alpha-1 isoforms, alpha-1A, B, C, D, E, and S. This gene encodes the alpha-1A subunit, which is predominantly expressed in neuronal tissue. Mutations in this gene are associated with 2 neurologic disorders, familial hemiplegic migraine and episodic ataxia 2. This gene also exhibits polymorphic variation due to (CAG)n-repeats. Multiple transcript variants encoding different isoforms have been found for this gene. In one set of transcript variants, the (CAG)n-repeats occur in the 3' UTR, and are not associated with any disease. But in another set of variants, an insertion extends the coding region to include the (CAG)n-repeats which encode a polyglutamine tract. Expansion of the (CAG)n-repeats from the normal 4-18 to 21-33 in the coding region is associated with spinocerebellar ataxia 6. [provided by RefSeq, Jul 2016]

Previous symbols:
  • CACNL1A4
  • SCA6
  • MHP1
  • MHP

MANE transcript

NM_001127222.2

Inheritance

AD

ClinVar variants

P:624U:1726B:1156

Top phenotype

Episodic ataxia, type 2; Migraine, familial hemiplegic 1; Spinocerebellar ataxia 6

gnomAD constraint

pLI —, LoF o/e 0.08

Max pathogenic AF

—

Genomic locus

chr19:13,206,442-13,624,489

External References & Databases

Transcript & Mutation Effects

hg38 • Region Span ~418.0 kb
Loading mutation effect viewer...

GenCC Phenotypes & Disease Associations

Curated gene-disease validity assertions and inheritance patterns

episodic ataxia type 2STRONG

Inheritance Pattern: AD

Disease ID:MONDO:0007163

Submitter: Labcorp Genetics (formerly Invitae)

developmental and epileptic encephalopathy, 42STRONG

Inheritance Pattern: AD

Disease ID:MONDO:0014917

Submitter: G2P

spinocerebellar ataxia type 6STRONG

Inheritance Pattern: AD

Disease ID:MONDO:0008457

Submitter: Labcorp Genetics (formerly Invitae)

undetermined early-onset epileptic encephalopathySUPPORTIVE

Inheritance Pattern: AD

Disease ID:MONDO:0018614

Submitter: Orphanet

benign paroxysmal torticollis of infancySUPPORTIVE

Inheritance Pattern: AD

Disease ID:MONDO:0019113

Submitter: Orphanet

familial or sporadic hemiplegic migraineSUPPORTIVE

Inheritance Pattern: AD

Disease ID:MONDO:0018925

Submitter: Orphanet

undetermined early-onset epileptic encephalopathyDEFINITIVE

Inheritance Pattern: AD

Disease ID:MONDO:0018614

Submitter: Illumina

spinocerebellar ataxia type 6SUPPORTIVE

Inheritance Pattern: AD

Disease ID:MONDO:0008457

Submitter: Orphanet

migraine, familial hemiplegic, 1STRONG

Inheritance Pattern: AD

Disease ID:MONDO:0020756

Submitter: Genomics England PanelApp

developmental and epileptic encephalopathy, 42STRONG

Inheritance Pattern: AD

Disease ID:MONDO:0014917

Submitter: Labcorp Genetics (formerly Invitae)

episodic ataxia type 2STRONG

Inheritance Pattern: AD

Disease ID:MONDO:0007163

Submitter: Genomics England PanelApp

spinocerebellar ataxia type 6STRONG

Inheritance Pattern: AD

Disease ID:MONDO:0008457

Submitter: Genomics England PanelApp

episodic ataxia type 2SUPPORTIVE

Inheritance Pattern: AD

Disease ID:MONDO:0007163

Submitter: Orphanet

migraine, familial hemiplegic, 1STRONG

Inheritance Pattern: AD

Disease ID:MONDO:0020756

Submitter: Labcorp Genetics (formerly Invitae)

spinocerebellar ataxia type 6STRONG

Inheritance Pattern: AD

Disease ID:MONDO:0008457

Submitter: Ambry Genetics

Lennox-Gastaut syndromeSUPPORTIVE

Inheritance Pattern: AD

Disease ID:MONDO:0016532

Submitter: Orphanet

episodic ataxia type 2DEFINITIVE

Inheritance Pattern: AD

Disease ID:MONDO:0007163

Submitter: Ambry Genetics

developmental and epileptic encephalopathy, 42MODERATE

Inheritance Pattern: AD

Disease ID:MONDO:0014917

Submitter: Ambry Genetics

migraine, familial hemiplegic, 1STRONG

Inheritance Pattern: AD

Disease ID:MONDO:0020756

Submitter: Ambry Genetics

Clinical Genomic Database (CGD)

Episodic ataxia, type 2; Migraine, familial hemiplegic 1; Spinocerebellar ataxia 6AD

Manifestation: Neurologic

Intervention: Neurologic; Pharmacogenomic

Rationale: Medical treatment (eg, 4-aminopyridine, acetazolamide, as well as other standard migraine-related medications to treat migraines) may be effective; In Migraine, familial hemiplegic 1, vasoconstricting agents (due to risk of stroke) and cerebral angiography (due to risk of precipitation of attack) should be avoided; In Spinocerebellar ataxia 6, ataxia may be managed medically (with acetazolamide); Vestibular symptoms may be managed medically (eg, with diphenhydramine, baclofen, and gabapentin. 4-aminopyridine)

Refs: 6684259; 3469025; 1575453; 7757080; 8898206; 14681882; 9311738; 9302278; 9259274; 9259275; 8734765 ; 9403486; 9345107; 8988170; 15210532; 9915947; 10668728; 11439943; 11673601; 12081723; 12056940; 12707077; 14681882; 14718690; 15136697; 15362569; 16186543; 15710862; 15747371; 17575281; 17142831; 18541804; 18685131; 20301319; 20301562; 19633872; 21734179; 20837964; 23934111; 27476654; 28856914; 31824404Source: CGD (NHGRI)

ClinVar Associated Diseases & Phenotypes

Reported disease conditions connected to CACNA1A variants in ClinVar

74 Conditions Cataloged
Developmental and epileptic encephalopathy, 42Total: 3062
Episodic ataxia type 2Total: 3049
not providedTotal: 1987
Inborn genetic diseasesTotal: 590
not specifiedTotal: 548
CACNA1A-related disorderTotal: 335
Migraine, familial hemiplegic, 1Total: 174
Spinocerebellar ataxia type 6Total: 162

ClinVar Variants & Pathogenicity by Type

Statistics based on transcript NM_001127222.2. Only rare variants are included.

We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.

Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.

EffectPLPVUSLBBSum
synonymous
39
clinvar
818
clinvar
21
clinvar
878
missense
44
clinvar
177
clinvar
1661
clinvar
307
clinvar
10
clinvar
2199
nonsense
74
clinvar
37
clinvar
3
clinvar
114
start loss
1
clinvar
1
frameshift
147
clinvar
63
clinvar
19
clinvar
229
splice donor/acceptor (+/-2bp)
23
clinvar
58
clinvar
4
clinvar
85
Total28933517261125313506

Highest pathogenic variant AF is 0.000116978495

Loading ClinVar variants...

Transcript Catalog

Annotated transcript isoforms across RefSeq and Ensembl databases

Showing 4 of 41 transcripts
Transcript IDSourceProtein IDCoding ExonsMANE Status
NM_001127222.2RefSeqNP_001120694.147MANE Select
ENST00000360228.11EnsemblENSP00000353362.547MANE Select
NM_000068.4RefSeqNP_000059.348Standard
NM_001127221.2RefSeqNP_001120693.147MANE Plus Clinical

Model Organisms & Knockout Phenotypes

Observed phenotypic effects in mouse and zebrafish models

Gene / ModelOrganismObserved Phenotype
cacna1abDanio rerio

Structure: slow muscle cell

Quality: non-contractile

abnormal

Gene Ontology (GO) Annotations & Pathways

Biological processes, molecular functions, cellular components and pathways

Pathways ConsensusPathDB

  • Synaptic vesicle cycle - Homo sapiens (human)
  • Retrograde endocannabinoid signaling - Homo sapiens (human)
  • GABAergic synapse - Homo sapiens (human)
  • Serotonergic synapse - Homo sapiens (human)
  • Dopaminergic synapse - Homo sapiens (human)

Biological Process

  • calcium ion transport
  • positive regulation of cytosolic calcium ion concentration
  • chemical synaptic transmission
  • cell death
  • regulation of ion transmembrane transport

Molecular Function

  • amyloid-beta binding
  • voltage-gated calcium channel activity
  • calcium channel activity
  • protein binding
  • high voltage-gated calcium channel activity

Cellular Component

  • nucleus
  • cytoplasm
  • plasma membrane
  • voltage-gated calcium channel complex
  • integral component of membrane

gnomAD Constraint

Source: gnomAD

Gene type
protein_coding
Transcript type
protein_coding
Transcript
ENST00000360228
Coding exons
47
Length
417549
Individuals with no LoFs
124643
Homozygous LoFs
0
Heterozygous LoFs
12
Defined
124655
p
0.0000481
Z-ScoreObservedExpectedObserved/ExpectedMutation RateTotal Possible
Missense5.788441.47e+30.5750.000097616214
Missense (PolyPhen)159372.910.426383690
Synonymous-0.2606216131.010.00004494918
Loss of Function9.2791170.07670.000006641264

Population LoF Frequency

PopulationCAFp-valueStatus
African0.0000660.000065rare
Latino/Admixed American00.0absent
Ashkenazi Jewish00.0absent
East Asian0.0000560.000056rare
Finnish00.0absent
European (Non-Finnish)0.0000840.000080rare
South Asian0.0000340.000033rare
Other00.0absent

dbNSFP Gene Annotations

Source: dbNSFP

Function
FUNCTION: Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1A gives rise to P and/or Q-type calcium currents. P/Q-type calcium channels belong to the 'high-voltage activated' (HVA) group and are specifically blocked by the spider omega-agatoxin-IVA (AC P54282) (By similarity). They are however insensitive to dihydropyridines (DHP). {ECO:0000250|UniProtKB:P54282, ECO:0000269|PubMed:10049321, ECO:0000269|PubMed:10753886, ECO:0000269|PubMed:11723274, ECO:0000269|PubMed:15293273, ECO:0000269|PubMed:19232643, ECO:0000269|PubMed:24836863, ECO:0000269|PubMed:26716990}.;
Disease
DISEASE: Spinocerebellar ataxia 6 (SCA6) [MIM:183086]: Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA6 is an autosomal dominant cerebellar ataxia (ADCA), mainly caused by expansion of a CAG repeat in the coding region of CACNA1A. There seems to be a correlation between the repeat number and earlier onset of the disorder. {ECO:0000269|PubMed:16325861, ECO:0000269|PubMed:20682717, ECO:0000269|PubMed:29053796, ECO:0000269|PubMed:8988170, ECO:0000269|PubMed:9302278, ECO:0000269|PubMed:9345107}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Migraine, familial hemiplegic, 1 (FHM1) [MIM:141500]: A subtype of migraine with aura associated with ictal hemiparesis and, in some families, cerebellar ataxia and atrophy. Migraine is a disabling symptom complex of periodic headaches, usually temporal and unilateral. Headaches are often accompanied by irritability, nausea, vomiting and photophobia, preceded by constriction of the cranial arteries. Migraine with aura is characterized by recurrent attacks of reversible neurological symptoms (aura) that precede or accompany the headache. Aura may include a combination of sensory disturbances, such as blurred vision, hallucinations, vertigo, numbness and difficulty in concentrating and speaking. {ECO:0000269|PubMed:10408532, ECO:0000269|PubMed:11409427, ECO:0000269|PubMed:11439943, ECO:0000269|PubMed:15032980, ECO:0000269|PubMed:18400034, ECO:0000269|PubMed:24836863, ECO:0000269|PubMed:26716990, ECO:0000269|PubMed:28900389, ECO:0000269|PubMed:8898206}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Episodic ataxia 2 (EA2) [MIM:108500]: An autosomal dominant disorder characterized by acetozolamide-responsive attacks of ataxia, migraine-like symptoms, interictal nystagmus, and cerebellar atrophy. {ECO:0000269|PubMed:10408533, ECO:0000269|PubMed:10987655, ECO:0000269|PubMed:11176968, ECO:0000269|PubMed:11723274, ECO:0000269|PubMed:12420090, ECO:0000269|PubMed:14718690, ECO:0000269|PubMed:15173248, ECO:0000269|PubMed:15293273, ECO:0000269|PubMed:18602318, ECO:0000269|PubMed:19232643, ECO:0000269|PubMed:20129625, ECO:0000269|PubMed:21696515, ECO:0000269|PubMed:8898206, ECO:0000269|PubMed:9302278}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Epileptic encephalopathy, early infantile, 42 (EIEE42) [MIM:617106]: A form of epileptic encephalopathy, a heterogeneous group of severe childhood onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. EIEE42 inheritance is autosomal dominant. {ECO:0000269|PubMed:27250579, ECO:0000269|PubMed:27476654}. Note=The disease is caused by mutations affecting the gene represented in this entry.;

Recessive Scores

pRec
0.559

Intolerance Scores

RVIS EVS
-1.78
RVIS percentile EVS
2.27

Essentials

Essential (CRISPR)
N
Essential (CRISPR2)
N
Essential (gene trap)
N
Indispensability pred.
E
Indispensability score
0.731

Gene Damage Prediction

AllRecessiveDominant
MendelianHighMediumMedium
Primary ImmunodeficiencyHighHighHigh
CancerHighHighHigh
For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.